
Covid vaccine row: Piyush Goyal slams K'taka CM for insulting Indian scientists, drugmakers
Speaking to the media, on the sidelines of IIT Madras Alumni Association's Sangam 2025 event in Bengaluru, Piyush Goyal praised the Indian scientists for developing Covid vaccine in record time and the pharmaceutical sector for making it cost-effective.
'Fake narratives can't dilute the extraordinary work done by our scientists and the pharma industry in our fight against Covid,' said Goyal.
'Such a big country like India was able to provide 250 crore vaccines for free, because the companies of our country had the strength to make the vaccine at a much lower cost,' he added.
His comments come in the wake of Siddaramaiah's recent post on social media platform X on 'the hasty approval and distribution of the Covid vaccine to the public'.
The CM linked it to the more than 20 heart attack-related deaths seen in Karnataka's Hassan district in just 40 days.
The Union Health Ministry, along with several scientists as well as pharma associations, has denied any link between Covid vaccines and the reported sudden deaths.
A joint clarification from the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), and the National Centre for Disease Control (NCDC) stated that ongoing surveillance and analyses have not revealed any significant deviation in patterns of cardiac-related deaths since before the pandemic.
'I feel that the Chief Minister here does not disrespect, he insults, and when he insults our scientists, our pharmacy, then I do not know what is the motive behind it?' Goyal said.
"Apologise to the Indian scientists and the pharmaceutical sector,' he added.
He also asked whether the CM and the Congress are working at the behest of foreign powers.
'Are these the foreign powers whose agenda they are running here, are the foreign powers who want to lure India's pharmacy, are they troubled by India's economic progress and development,' Goyal said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


United News of India
an hour ago
- United News of India
Dr Jitendra Singh launches National BioBank' for personalised healthcare for every Indian
New Delhi, July 6 (UNI) Union Minister of State for Science and Technology and Vice President of CSIR, Dr. Jitendra Singh, today inaugurated the Phenome India National Biobank National aiming to promise personalised healthcare for every Indian based on their genetic background, lifestyle and envirornment. Designed on the lines of the UK Biobank but contextualised for Indian diversity, the biobank will collect and analyse genetic, lifestyle and clinical data from 10,000 individuals across the country. It is housed at the Council of Scientific and Industrial Research - Institute of Genomics and Integrative Biology (CSIR-IGIB) here. Dr Singh who also launched India's first longitudinal population health study on the occasion, said, 'This is a decisive step towards individualised healthcare, one where treatment can be tailored to a person's genetic background, lifestyle and environment.' The Biobank will support long-term research into a host of conditions including diabetes, cardiovascular disorders, rare genetic diseases and cancers, with a view to improve diagnostics, therapeutic targeting and disease prevention strategies, said a statement from the Ministry. Highlighting the unique metabolic and epidemiological characteristics observed in the Indian population, Dr. Singh underscored the need for population-specific strategies. 'Indians may appear lean but still harbour central obesity, a known risk factor for diabetes and cardiovascular diseases,' he noted. 'Our conditions are complex and deeply heterogeneous. This is where the Biobank becomes vital.' CSIR-IGIB's current projects, including indigenous CRISPR trials for sickle cell anaemia, efforts against antimicrobial resistance (AMR), and diagnostics for liver fibrosis and rare disorders, are expected to greatly benefit from the high-resolution health data generated through the Biobank. Calling for enhanced synergy between research institutions, government departments and the private sector, Dr. Singh emphasised the need to bridge lab-based research with social impact. 'Scientific breakthroughs must transition from the bench to the bedside—and ultimately to the marketplace,' he said. Dr. N. Kalaiselvi, Director General of CSIR and Secretary, DSIR, emphasised its potential to evolve into a global benchmark. 'This is a baby step today, but it holds the promise to rival international projects in both scale and depth,' she said. Dr. Kalaiselvi also reiterated CSIR's efforts in developing affordable diagnostics and CRISPR-based therapies in collaboration with tribal communities, particularly for sickle cell anaemia—a disease with high prevalence in certain regions of India. Reflecting on IGIB's pioneering legacy in genomics, Dr. Souvik Maiti, Director of CSIR-IGIB, noted that the institute was the first in India to begin decoding the human genome, even before sequencing tools became widely available. He cited IGIB's development of over 300 genetic diagnostics, its leadership in COVID-19 genome surveillance, and India's first Drug Genome Project. IGIB's expanding research now includes women-centric studies, breast cancer genomics, and innovative work in space biology and AI-assisted pilot fitness assessments in collaboration with the Indian Air Force, said the statement. UNI AJ GNK


Deccan Herald
an hour ago
- Deccan Herald
China will not allow external interference in Dalai Lama's reincarnation process, Beijing's envoy to Delhi says
🔹It has been noted that some Indian official recently made some remarks regarding the reincarnation of the Dalai Lama. 🔹Chinese government opposes any attempts by overseas organizations or individuals to interfere in or dictate the reincarnation process. Xizang is an…
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Life for Indian students in Trump's America gets increasingly tougher
Indian students putting the American dream on hold premium Sanket Koul New Delhi Listen to This Article With a dream to study law in the United States (US), 23 year-old James (name changed) had taken the now-defunct Law School Admission Test (LSAT) in 2024. While he got 98.7 percentile in the exams, his wish to study in the US was put on hold due to the recent changes in student visa norms. 'I was advised by my friends in the US to not apply this year,' he said. There are two reasons why, he said. 'One is the association in terms of you being a foreigner and then there is the added fact that you are consistently